Peptide Library
Research reference cards including mechanism, dosage guidance, cycle length, frequency and synergistic peptides.
Epitalon
Research compound reference
Mechanism
Telomere/clock-gene regulation, melatonin production
Typical Dose
5-10mg daily
Cycle Length
1.5-3 weeks
Frequency
Daily
Research Areas
- Sleep quality
- Circadian regularity
- Stress resilience
Synergistic Peptides
DSIP
Research compound reference
Mechanism
Modulates sleep-arousal networks via hypothalamic signalling
Typical Dose
100-400 mcg
Cycle Length
2-4 weeks
Frequency
Daily
Research Areas
- Faster sleep onset
- Fewer awakenings
- Improved sleep continuity
Synergistic Peptides
CJC-1295 no-DAC
Research compound reference
Mechanism
GHRH-R agonist; ~30 min half-life, daily/multi-daily cadence
Typical Dose
100-300 mcg daily
Cycle Length
8-12 weeks
Frequency
Daily
Research Areas
- Pulsatile GH release
- Sleep & recovery
- Daily-cadence GHRH
Synergistic Peptides
5-Amino-1MQ
Research compound reference
Mechanism
The NNMT Inhibitor for Fat Cell Metabolism
Typical Dose
250–500 mcg
Cycle Length
4–6 weeks- 8-12 weeks off
Frequency
subcutaneous daily
Research Areas
- Fat loss
- Metabolic flexibility
- Insulin sensitivity
Synergistic Peptides
BPC-157
Research compound reference
Mechanism
Angiogenesis, NO signalling, fibroblast migration
Typical Dose
250–500mcg
Cycle Length
4–12 weeks
Frequency
Daily
Research Areas
- Systemic healing
- Gut barrier support
- Tissue regeneration
Synergistic Peptides
NAD+
Research compound reference
Mechanism
Universal cofactor for ATP and sirtuin activity
Typical Dose
50-250mg 2-3x- weekly
Cycle Length
2-12 weeks
Frequency
2-3 x weekly
Research Areas
- Restores cellular energy
- Supports DNA repair
- Enhances mitochondrial function
Synergistic Peptides
Retatrutide
Research compound reference
Mechanism
GLP-1 (satiety), GIP (insulinotropic), glucagon (lipolysis) agonist
Typical Dose
0.25-12mg weekly
Cycle Length
12-48 weeks
Frequency
weekly
Research Areas
- Aggressive fat loss
- Energy expenditure
- Satiety control
Synergistic Peptides
MOTS-c
Research compound reference
Mechanism
AMPK activation, metabolic flexibility enhancement
Typical Dose
5-10mg 2-3x weekly
Cycle Length
8-12 weeks
Frequency
2-3 x- weekly
Research Areas
- Fat oxidation
- Training tolerance
- Metabolic flexibility
Synergistic Peptides
GHK-CU
Research compound reference
Mechanism
Up-regulates collagen/elastin, down-regulates MMPs
Typical Dose
1-2.5mg 3x/week
Cycle Length
6-8 weeks
Frequency
3x/week
Research Areas
- Skin remodelling
- Scar quality
- Hair support
Synergistic Peptides
KPV
Research compound reference
Mechanism
a-MSH fragment, NF-kB down-regulation, mast-cell stabilisation
Typical Dose
200–500mcg
Cycle Length
4–8 weeks
Frequency
Daily
Research Areas
- Mucosal inflammation
- IBD symptom support
- Post-injury swelling
Synergistic Peptides
Tesamorelin
Research compound reference
Mechanism
Stimulates pituitary GH release, IGF-1 elevation, lipolysis
Typical Dose
1-2mg daily
Cycle Length
12-16 weeks
Frequency
Daily
Research Areas
- Visceral fat reduction
- Improved body composition
- Enhanced recovery
Synergistic Peptides
Melanotan II
Research compound reference
Mechanism
Cyclic peptide; activates MC1R/MC3R/MC4R/MC5R - tanning, sexual function, appetite suppression
Typical Dose
250–500mcg
Cycle Length
1-4 weeks
Frequency
Daily
Research Areas
- Tanning without UV
- Sexual function
- Appetite reduction
Synergistic Peptides
For laboratory research use only.
ELIXA Labs supplies research compounds exclusively for laboratory, analytical and scientific investigation. Products are not intended for human consumption.